Top 10 Tokenized Equities by 1-Month Price Change: Quantum Leads at +145%

The top tokenized equity by one-month price change is Quantum ($QMCO), up +145% as of August 14, 2026, according to Defillama. Rare Element Resources ($REEMF) follows at +121%, and Atlassian ($TEAM) sits fifth at +86.3% despite carrying a $26.5 billion market cap, roughly 45 times larger than the next-biggest name on the list.

Key takeaways

• Quantum ($QMCO) leads all tokenized equities with a +145% one-month gain, on a market cap of just $361 million.
• Atlassian ($TEAM) is the only large-cap name in the top 10, with a $26.5 billion market cap and +86.3% gain, accounting for roughly 68% of the group's combined ~$38.8 billion market cap.
• Six of the ten stocks are biotech, medtech, or hardware companies: Everforth, Netlist, Forte Biosciences, Pulse Biosciences, Ethos Technologies, and Varex Imaging.
• Utz Snacks ($UTZ), a $1.25 billion snack brand, posted +89.3%, outperforming five of the six biotech/medtech/hardware names on the list.
• The spread between #1 and #10 is 70 percentage points (+145% versus +75.0%), meaning even the tenth-ranked stock, Varex Imaging ($VREX), roughly doubled in price momentum terms relative to a flat month.

What are the top 10 tokenized equities by 1-month price change?

The full list spans a 70-percentage-point range, from Quantum's +145% down to Varex Imaging's +75.0%, with market caps ranging from $361 million to $26.5 billion. Every name on the list at least came close to doubling in price over 30 days, per Defillama data as tracked in the August 14, 2026 snapshot.

Rank	Company	Ticker	1M Price Change	Market Cap	Price
1	Quantum	$QMCO	+145%	$361M	$24.68
2	Rare Element Resources	$REEMF	+121%	$600M	$0.93
3	Everforth	$EFOR	+95.5%	$1.38B	$33.45
4	Utz Snacks	$UTZ	+89.3%	$1.25B	$14.16
5	Atlassian	$TEAM	+86.3%	$26.5B	$165.98
6	Netlist	$NLST	+78.4%	$1.58B	$4.96
7	Forte Biosciences	$FBRX	+77.9%	$1.07B	$76.86
8	Pulse Biosciences	$PLSE	+76.4%	$3.07B	$44.92
9	Ethos Technologies	$LIFE	+75.4%	$2.19B	$34.80
10	Varex Imaging	$VREX	+75.0%	$780M	$18.50

Why is Atlassian the outlier on this list?

Atlassian sits at #5 with a +86.3% one-month gain, but its $26.5 billion market cap dwarfs every other stock in the top 10, none of which exceeds $3.1 billion. That scale gap means Atlassian's move required real capital inflows across a mature, widely held stock, while the other nine names are small and mid-cap, where the same percentage swing can be produced by comparatively modest trading volume. In dollar terms, Atlassian's market cap gain implies far more capital rotation than any other stock on the list, even though its percentage change ranks only fifth. This is the core distinction the data draws out: momentum at $26.5 billion is a fundamentally different phenomenon than momentum at $361 million.

For context on how price momentum differs from underlying protocol or platform activity, see protocol revenue explained, which breaks down what actual usage-driven metrics look like versus pure price action.

What does small and mid-cap momentum reveal here?

Outside of Atlassian, the remaining nine stocks range from $361 million to $3.07 billion in market cap, and the post frames their gains as event-driven rather than trend-driven. Quantum's +145% on a $361 million base and Rare Element Resources' +121% on $600 million are the two smallest-cap, largest-gain pairings on the list, suggesting concentrated buying pressure on thin float rather than broad-based rotation. Six of the ten names — Everforth, Netlist, Forte Biosciences, Pulse Biosciences, Ethos Technologies, and Varex Imaging — sit in biotech, medtech, or hardware, sectors prone to sharp, catalyst-driven repricing around trial results, contracts, or product news. That sector concentration (60% of the list) is itself a data point: it signals the rally is narrower than it first appears, clustered in a handful of industries rather than spread evenly across the market.

Why does Utz Snacks stand out among biotech names?

Utz Snacks ranks fourth at +89.3%, ahead of five of the six biotech, medtech, and hardware stocks on the list, despite being a consumer packaged goods company with a $1.25 billion market cap. This matters because Utz's move contradicts the sector-driven pattern seen elsewhere on the list — a snack brand outperforming clinical-stage biotech names implies its rally is not tied to the same event-driven catalysts (trial data, regulatory news) that typically move healthcare stocks. The post explicitly labels Utz the